136 related articles for article (PubMed ID: 38164873)
21. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
Afilalo M; Morlion B
Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy of Tapentadol for Neuropathic Pain in Cancer].
Takahara Y; Tanahashi J; Murota K; Imai M; Takagi Y; Kimata T
Gan To Kagaku Ryoho; 2021 Jun; 48(6):811-814. PubMed ID: 34139729
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of tapentadol for the treatment of chronic low back pain in elderly patients.
Freo U; Furnari M; Ambrosio F; Navalesi P
Aging Clin Exp Res; 2021 Apr; 33(4):973-982. PubMed ID: 32418129
[TBL] [Abstract][Full Text] [Related]
24. Tapentadol prolonged release for managing moderate to severe chronic neck pain with or without a neuropathic component.
Coluzzi F; Pergolizzi JV; Giordan E; Locarini P; Boaro A; Billeci D
Curr Med Res Opin; 2020 Apr; 36(4):651-659. PubMed ID: 31983248
[No Abstract] [Full Text] [Related]
25. Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists.
Schwittay A; Schumann C; Litzenburger BC; Schwenke K
J Pain Palliat Care Pharmacother; 2013 Aug; 27(3):225-34. PubMed ID: 23957433
[TBL] [Abstract][Full Text] [Related]
26. Management of severe chronic pain with tapentadol prolonged release - long-term data from pain specialists.
Strick V
Curr Med Res Opin; 2014 Oct; 30(10):2085-92. PubMed ID: 24983745
[TBL] [Abstract][Full Text] [Related]
27. Tapentadol prolonged release in association with analgesic radiofrequency for the treatment of chronic lumbar radicular pain: an observational, prospective study.
Visconti C; Mastroluca A; Varano L; Del Gaudio A
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):27-34. PubMed ID: 31755082
[TBL] [Abstract][Full Text] [Related]
28. [Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone].
Kern KU; Krings D; Waldmann-Rex S
MMW Fortschr Med; 2014 Jul; 156 Suppl 2():54-63. PubMed ID: 25351028
[TBL] [Abstract][Full Text] [Related]
29. Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial.
Buynak R; Rappaport SA; Rod K; Arsenault P; Heisig F; Rauschkolb C; Etropolski M
Clin Ther; 2015 Nov; 37(11):2420-38. PubMed ID: 26428249
[TBL] [Abstract][Full Text] [Related]
30. Tapentadol extended release for chronic pain patients.
Taylor R; Pergolizzi JV; Raffa RB
Adv Ther; 2013 Jan; 30(1):14-27. PubMed ID: 23328938
[TBL] [Abstract][Full Text] [Related]
31. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy.
Niesters M; Proto PL; Aarts L; Sarton EY; Drewes AM; Dahan A
Br J Anaesth; 2014 Jul; 113(1):148-56. PubMed ID: 24713310
[TBL] [Abstract][Full Text] [Related]
32. Tapentadol for Cancer Pain Management: A Narrative Review.
Carmona-Bayonas A; Jiménez Fonseca P; Virizuela Echaburu J
Pain Pract; 2017 Nov; 17(8):1075-1088. PubMed ID: 28084045
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Effectiveness and Tolerability of Pain Treatment with Tapentadol Prolonged Release.
Mateos RG; Bernal DS; Morera LMT; Ferri CM; Escobar AE
Pain Physician; 2021 Jan; 24(1):E75-E85. PubMed ID: 33400440
[TBL] [Abstract][Full Text] [Related]
34. Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.
Baron R; Eberhart L; Kern KU; Regner S; Rolke R; Simanski C; Tölle T
Pain Pract; 2017 Jun; 17(5):678-700. PubMed ID: 27611642
[TBL] [Abstract][Full Text] [Related]
35. A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain.
Etropolski M; Lange B; Goldberg J; Steup A; Rauschkolb C
J Opioid Manag; 2013; 9(5):343-56. PubMed ID: 24353047
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and tolerability of tapentadol sustained release in the Australian setting.
Russo MA; Santarelli DM
J Opioid Manag; 2016; 12(3):187-96. PubMed ID: 27435439
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine.
Ikenberg R; Hertel N; Moore RA; Obradovic M; Baxter G; Conway P; Liedgens H
J Med Econ; 2012; 15(4):724-36. PubMed ID: 22364286
[TBL] [Abstract][Full Text] [Related]
38. [Clinical practice data regarding tapentadol prolonged release treatment for severe chronic pain - improvement of analgesia, functional competence and quality of life in particular under tapentadol monotherapy].
Lange T; Krings D; Waldmann-Rex S
MMW Fortschr Med; 2015 Apr; 157(157 Suppl 4):12-21. PubMed ID: 26013114
[TBL] [Abstract][Full Text] [Related]
39. [Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists].
Schwittay A
MMW Fortschr Med; 2013 Jan; 155(1):64. PubMed ID: 23573727
[No Abstract] [Full Text] [Related]
40. Pain response and quality of life assessment in patients with moderate/severe neuropathic pain due to bone metastasis undergoing treatment with palliative radiotherapy and tapentadol: A prospective multicentre pilot study.
Cacicedo J; Ciria JP; Morillo V; Martinez-Indart L; Gómez-Iturriaga A; Del Hoyo O; Büchser D; Frias A; San Miguel I; Suarez F; Casquero F
J Med Imaging Radiat Oncol; 2020 Dec; 64(6):859-865. PubMed ID: 32729219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
